OneMedNet receives high‑six‑figure add‑on order for clinical AI data
An existing customer expands data volume by 150 per cent, but delivery timing and the exact contract value remain undisclosed.
Julian Okafor
A repeat clinical-data order adds contracted business for an AI supplier while leaving the delivery timetable and near-term revenue contribution undisclosed. OneMedNet Corporation NASDAQONMD, a Minnesota supplier of de-identified medical imaging and clinical records, said on Nov. 3 that an existing customer increased data volume by 150 per cent through a high-six-figure add-on order.
The customer exercised an expansion option in a multiyear agreement announced Sept. 30. OneMedNet did not disclose the customer's identity, the exact order value, payment terms or a delivery deadline in the Nov. 3 announcement, leaving the amount attributable to any reporting quarter unspecified.
Shares traded lower at US$4.20 on Nasdaq at 9:30 a.m. EST on Nov. 3, according to NASDAQONMD. That early quote followed the company's order announcement and represents an opening snapshot rather than a closing market response.
The original Sept. 30 agreement was described as a seven-figure licence covering multiple years. It provides data for the customer's AI-enabled clinical and diagnostic models, alongside a derivative dataset the customer intends to sell through its own distribution channel.
The Expansion Adds Data To An Existing Licence
The new order expands the supply relationship established in September rather than adding a separately identified customer. OneMedNet says the additional volume is needed to support that customer's derivative data offering; the announcement does not report sales of the derivative to end users.
Under the original arrangement, the customer plans to combine its molecular datasets with OneMedNet's imaging and longitudinal clinical records. The resulting product would connect those sources for life-sciences customers, while the underlying data would continue to reach the partner through OneMedNet's iRWD platform.
"Within weeks of signing on September 30, our customer exercised its expansion option to support its growing derivative data offering, and we expect the relationship to grow as its solution does," OneMedNet chief executive Aaron Green said.
The November announcement retains the potential for recurring sublicensing income when the partner licenses the derivative dataset to end customers. Neither announcement gives a sublicensing rate or a minimum downstream sales commitment, so the add-on order does not establish how much recurring income that channel will generate.
OneMedNet retains rights to the source data, and end customers cannot relicense or resell the underlying records. The September agreement therefore distinguishes the partner's commercial derivative from the clinical information used to create it, preserving a restriction on further distribution of OneMedNet's own data.
The company says its network spans more than 2,300 healthcare partner sites, with more than 90 million patient journeys and 270 million studies as of the Nov. 3 release. Those are network-wide figures; the announcement does not specify how many records or studies the expanded order will deliver.
Bookings Have A Year-End Delivery Test
The order follows a Sept. 18 bookings update reporting approximately US$16.2 million of contracted demand for 2026 to that date. OneMedNet said a significant portion was expected to be delivered during the remainder of the year, across datasets, data-plus-licence arrangements and multiyear platform access.
The September update said approximately 50 per cent of contracts booked during 2026 were with new customers. November's expansion is a specific example of follow-on demand from an existing relationship, although neither release gives that customer's share of total bookings or revenue.
That bookings total predates both the September agreement and November's expansion, so it cannot serve as an updated order-book figure. The Sept. 18 release also identified customer acceptance of delivered datasets as a condition affecting conversion of bookings into revenue, alongside delivery timing.
The scale of contracted demand contrasts with the company's earlier sales base. In its April 6 financial update, OneMedNet reported 2025 real-world-data revenue of US$1.254 million. That compared with US$292,000 in 2024, while the multiyear nature of newer contracts prevents treating their full value as annual sales.
Elsewhere in listed precision-medicine software, SOPHiA GENETICS NASDAQSOPH, an AI-driven precision-medicine company, reported third-quarter revenue of US$24.3 million on Nov. 3, up 25 per cent. Its reported sales provide a sector comparison with the contracted-demand figures, following Mugglehead's coverage of its quarterly results.
Read more: SOPHiA GENETICS reports 25 per cent revenue growth and holds sales range
For OneMedNet, the next dated delivery window remains the remainder of 2026 identified in its Sept. 18 update. That window ends Dec. 31; the Nov. 3 release sets no separate delivery date or revenue-recognition timetable for the add-on order.
